Processa Pharmaceuticals, Inc. is focused on the development of drug products which intended to improve the survival and/or quality of life for patients who have unmet medical need. Processa Pharmaceuticals Inc., formerly known as Heatwurx Inc., is based in HANOVER, United States.
Revenue (Most Recent Fiscal Year) | -- |
Net Income (Most Recent Fiscal Year) | $-11.12M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.40 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -141.42% |
Return on Assets (Trailing 12 Months) | -122.25% |
Current Ratio (Most Recent Fiscal Quarter) | 7.70 |
Quick Ratio (Most Recent Fiscal Quarter) | 7.70 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $4.05 |
Earnings per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Year) | -- |
Diluted Earnings per Share (Trailing 12 Months) | $-7.44 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 2.86M |
Free Float | 2.22M |
Market Capitalization | $4.63M |
Average Volume (Last 20 Days) | 0.43M |
Beta (Past 60 Months) | 0.53 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 22.20% |
Percentage Held By Institutions (Latest 13F Reports) | 91.93% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |